Article Type
Changed
Wed, 10/18/2017 - 10:41
Display Headline
Menstrual manipulation

To the Editor: In the article, “Menstrual manipulation: Options for suppressing the cycle,”1 the authors described advantages and disadvantages of various hormone-based methods of menstrual manipulation, including prolonged use of oral contraceptives. We believe the authors underemphasized the risks associated with oral contraceptives. Blood clots, stroke, and death are often included in print and television ads by law firms recruiting patients harmed by these drugs. In addition, the authors failed to mention the risk of premenopausal breast cancer due to oral contraceptives, which are now classified as group 1 carcinogens by the World Health Organization.2

In October 2006, we published the most current meta-analysis to date regarding oral contraceptive use and the risk of premenopausal breast cancer.3 We found that 21 out of 23 studies showed a positive trend or positive risk for premenopausal breast cancer with oral contraceptive use prior to first-term pregnancy. This resulted in a highly statistically significant cumulative risk of 44% (ie, odds ratio 1.44, 95% confidence interval 1.24–1.68). Our meta-analysis remains the most recent study in this area and updates the Oxford pooled analysis,4 which relied on older studies with older women (two-thirds of whom were over age 45).

A more recent collaborative study coauthored by investigators from the National Cancer Institute, the Hutchinson Cancer Research Center, and the University of Washington includes oral contraceptives in the list of risk factors for breast cancer in younger women.5 We ask your readers to consider that patients are entitled to know about this important risk factor before making a decision regarding hormonal menstrual manipulation.

References
  1. Hicks CW, Rome ES. Menstrual manipulation: options for suppressing the cycle. Clev Clin J Med 2010; 77:445453.
  2. Cogliano V, Grosse Y, Baan R, et al; WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005; 6:552553.
  3. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 2006; 81:12901302.
  4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996; 54(3 suppl):1S106S.
  5. Dolle JM, Daling JR, White E, et al. Risk factors of triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009; 18:11571166.
Article PDF
Author and Disclosure Information

Chris Kahlenborn, MD
Department of Internal Medicine, Holy Spirit Hospital, Camp Hill, PA

Walter B. Severs, PhD, FCP
Professor Emeritus of Pharmacology, Penn State College of Medicine, Hershey, PA

Issue
Cleveland Clinic Journal of Medicine - 78(3)
Publications
Topics
Page Number
145-150
Sections
Author and Disclosure Information

Chris Kahlenborn, MD
Department of Internal Medicine, Holy Spirit Hospital, Camp Hill, PA

Walter B. Severs, PhD, FCP
Professor Emeritus of Pharmacology, Penn State College of Medicine, Hershey, PA

Author and Disclosure Information

Chris Kahlenborn, MD
Department of Internal Medicine, Holy Spirit Hospital, Camp Hill, PA

Walter B. Severs, PhD, FCP
Professor Emeritus of Pharmacology, Penn State College of Medicine, Hershey, PA

Article PDF
Article PDF
Related Articles

To the Editor: In the article, “Menstrual manipulation: Options for suppressing the cycle,”1 the authors described advantages and disadvantages of various hormone-based methods of menstrual manipulation, including prolonged use of oral contraceptives. We believe the authors underemphasized the risks associated with oral contraceptives. Blood clots, stroke, and death are often included in print and television ads by law firms recruiting patients harmed by these drugs. In addition, the authors failed to mention the risk of premenopausal breast cancer due to oral contraceptives, which are now classified as group 1 carcinogens by the World Health Organization.2

In October 2006, we published the most current meta-analysis to date regarding oral contraceptive use and the risk of premenopausal breast cancer.3 We found that 21 out of 23 studies showed a positive trend or positive risk for premenopausal breast cancer with oral contraceptive use prior to first-term pregnancy. This resulted in a highly statistically significant cumulative risk of 44% (ie, odds ratio 1.44, 95% confidence interval 1.24–1.68). Our meta-analysis remains the most recent study in this area and updates the Oxford pooled analysis,4 which relied on older studies with older women (two-thirds of whom were over age 45).

A more recent collaborative study coauthored by investigators from the National Cancer Institute, the Hutchinson Cancer Research Center, and the University of Washington includes oral contraceptives in the list of risk factors for breast cancer in younger women.5 We ask your readers to consider that patients are entitled to know about this important risk factor before making a decision regarding hormonal menstrual manipulation.

To the Editor: In the article, “Menstrual manipulation: Options for suppressing the cycle,”1 the authors described advantages and disadvantages of various hormone-based methods of menstrual manipulation, including prolonged use of oral contraceptives. We believe the authors underemphasized the risks associated with oral contraceptives. Blood clots, stroke, and death are often included in print and television ads by law firms recruiting patients harmed by these drugs. In addition, the authors failed to mention the risk of premenopausal breast cancer due to oral contraceptives, which are now classified as group 1 carcinogens by the World Health Organization.2

In October 2006, we published the most current meta-analysis to date regarding oral contraceptive use and the risk of premenopausal breast cancer.3 We found that 21 out of 23 studies showed a positive trend or positive risk for premenopausal breast cancer with oral contraceptive use prior to first-term pregnancy. This resulted in a highly statistically significant cumulative risk of 44% (ie, odds ratio 1.44, 95% confidence interval 1.24–1.68). Our meta-analysis remains the most recent study in this area and updates the Oxford pooled analysis,4 which relied on older studies with older women (two-thirds of whom were over age 45).

A more recent collaborative study coauthored by investigators from the National Cancer Institute, the Hutchinson Cancer Research Center, and the University of Washington includes oral contraceptives in the list of risk factors for breast cancer in younger women.5 We ask your readers to consider that patients are entitled to know about this important risk factor before making a decision regarding hormonal menstrual manipulation.

References
  1. Hicks CW, Rome ES. Menstrual manipulation: options for suppressing the cycle. Clev Clin J Med 2010; 77:445453.
  2. Cogliano V, Grosse Y, Baan R, et al; WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005; 6:552553.
  3. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 2006; 81:12901302.
  4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996; 54(3 suppl):1S106S.
  5. Dolle JM, Daling JR, White E, et al. Risk factors of triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009; 18:11571166.
References
  1. Hicks CW, Rome ES. Menstrual manipulation: options for suppressing the cycle. Clev Clin J Med 2010; 77:445453.
  2. Cogliano V, Grosse Y, Baan R, et al; WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005; 6:552553.
  3. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 2006; 81:12901302.
  4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996; 54(3 suppl):1S106S.
  5. Dolle JM, Daling JR, White E, et al. Risk factors of triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009; 18:11571166.
Issue
Cleveland Clinic Journal of Medicine - 78(3)
Issue
Cleveland Clinic Journal of Medicine - 78(3)
Page Number
145-150
Page Number
145-150
Publications
Publications
Topics
Article Type
Display Headline
Menstrual manipulation
Display Headline
Menstrual manipulation
Sections
Disallow All Ads
Alternative CME
Article PDF Media